Core Laboratories Inc. (NYSE:CLB) Shares Bought by T. Rowe Price Investment Management Inc.

T. Rowe Price Investment Management Inc. raised its stake in Core Laboratories Inc. (NYSE:CLB - Free Report) by 4.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,158,702 shares of the oil and gas company's stock after acquiring an additional 46,941 shares during the period. T. Rowe Price Investment Management Inc. owned 2.47% of Core Laboratories worth $20,058,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Assetmark Inc. purchased a new stake in Core Laboratories in the 4th quarter valued at $26,000. Smartleaf Asset Management LLC raised its position in Core Laboratories by 173.8% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,037 shares of the oil and gas company's stock worth $35,000 after acquiring an additional 1,293 shares in the last quarter. Nisa Investment Advisors LLC increased its holdings in shares of Core Laboratories by 2,688.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,426 shares of the oil and gas company's stock valued at $42,000 after purchasing an additional 2,339 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Core Laboratories by 843.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,284 shares of the oil and gas company's stock valued at $57,000 after purchasing an additional 2,936 shares during the period. Finally, KLP Kapitalforvaltning AS purchased a new stake in Core Laboratories during the fourth quarter worth about $149,000. Hedge funds and other institutional investors own 97.81% of the company's stock.

Core Laboratories Trading Up 4.2 %

Shares of Core Laboratories stock traded up $0.49 during trading hours on Friday, reaching $12.17. 144,281 shares of the company's stock were exchanged, compared to its average volume of 395,256. Core Laboratories Inc. has a 52-week low of $10.14 and a 52-week high of $25.13. The company has a fifty day moving average of $13.59 and a 200-day moving average of $16.98. The company has a current ratio of 2.32, a quick ratio of 1.71 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $570.52 million, a price-to-earnings ratio of 18.43, a price-to-earnings-growth ratio of 0.99 and a beta of 1.99.

Core Laboratories (NYSE:CLB - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The oil and gas company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.01). Core Laboratories had a return on equity of 16.24% and a net margin of 5.99%. The business had revenue of $123.59 million during the quarter, compared to analyst estimates of $125.09 million. During the same period in the previous year, the company earned $0.19 EPS. Core Laboratories's revenue was down 4.7% on a year-over-year basis. Sell-side analysts forecast that Core Laboratories Inc. will post 0.96 EPS for the current fiscal year.

Core Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, May 27th. Stockholders of record on Monday, May 5th will be issued a $0.01 dividend. This represents a $0.04 annualized dividend and a dividend yield of 0.33%. The ex-dividend date is Monday, May 5th. Core Laboratories's dividend payout ratio (DPR) is presently 6.78%.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on CLB. StockNews.com cut Core Laboratories from a "hold" rating to a "sell" rating in a report on Friday, April 25th. Citigroup upgraded shares of Core Laboratories from a "sell" rating to a "neutral" rating and boosted their price objective for the stock from $15.00 to $16.00 in a research report on Wednesday, March 12th. Finally, Stifel Nicolaus cut their target price on shares of Core Laboratories from $19.00 to $15.00 and set a "hold" rating for the company in a research report on Tuesday, April 15th. Two research analysts have rated the stock with a sell rating and three have given a hold rating to the company's stock. According to MarketBeat.com, Core Laboratories presently has an average rating of "Hold" and a consensus price target of $15.75.

Core Laboratories Profile

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.